-
91.发明公开公开(公告)号：US20240285797A1
公开(公告)日：2024-08-29
申请号：US18412351
申请日：2024-01-12
IPC分类号： A61K48/00 , A61K35/14 , C07K14/705 , C12N9/22 , C12N15/88
CPC分类号： A61K48/005 , C07K14/705 , C12N9/22 , C12N15/88 , A61K35/14
摘要： Compositions and methods that rapidly and selectively modify hematopoietic stem cells (or cells derived therefrom) to achieve therapeutic objectives by providing for transient expression of nucleic acids are described. The transient expression leads to permanent therapeutic changes in the modified cells, referred to herein as “hit and run” effects.
-
公开(公告)号：US20240219385A1
公开(公告)日：2024-07-04
申请号：US18557406
申请日：2022-04-28
发明人： Thomas F. BUMOL , Xiaojun LI , Peter SKENE , Gregory Lee SZETO , Aarthi TALLA , Troy TORGERSON , Mark-Phillip PEBWORTH , Suhas VASAIKAR , Juliana M. MCELRATH
IPC分类号： G01N33/569
CPC分类号： G01N33/56983 , G01N2333/165 , G01N2333/521 , G01N2333/525 , G01N2333/5409 , G01N2333/5431 , G01N2333/5434 , G01N2333/5443 , G01N2333/545 , G01N2333/57 , G01N2333/70521
摘要： In various embodiments, provided are immune response signatures that can be used for the diagnosis, monitoring, and treatment of long-term diseases and inflammatory disorders caused by viral infections. In some embodiments, the viral infection is SARS-CoV-2 infection. In some embodiments, the long-term disease is post-acute sequelae of SARS-CoV-2 infection (PASC).
-
公开(公告)号：US12018250B2
公开(公告)日：2024-06-25
申请号：US16341290
申请日：2017-10-13
CPC分类号： C12N15/1027 , C12N15/10 , C12N15/102 , C12N15/11 , C12N15/113 , C12Q1/689 , C12N15/09 , C12N15/64 , C12N15/74 , C12N2310/20 , C12N2310/33 , C12N2310/333 , C12N2330/50 , C12Q2600/154 , C12Q2600/156
摘要： The present invention features modified polynucleotide sequences that mimic host cell DNA and methods of using such sequences for the genetic engineering of bacteria that are otherwise genetically intractable.
-
公开(公告)号：US12016880B2
公开(公告)日：2024-06-25
申请号：US17565885
申请日：2021-12-30
发明人： Mark B. Roth , Michael L. Morrison , Akiko Iwata
CPC分类号： A61K33/18 , A61K9/0053 , A61K33/00 , A61K33/04 , A61K33/16 , A61K38/063 , Y02A50/30 , A61K33/04 , A61K2300/00 , A61K33/18 , A61K2300/00 , A61K33/16 , A61K2300/00
摘要： The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.
-
公开(公告)号：US12012443B2
公开(公告)日：2024-06-18
申请号：US17166903
申请日：2021-02-03
IPC分类号： C07K14/705 , A61K35/17 , C07K14/725 , C12N5/0783 , A61K38/00 , A61K48/00
CPC分类号： C07K14/70596 , A61K35/17 , C07K14/70503 , C07K14/70507 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C12N5/0636 , C12N5/0637 , C12N5/0638 , A61K38/00 , A61K48/00 , C07K2319/03 , C07K2319/74 , C12N2510/00
摘要： Described herein are immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. Some immunomodulatory fusion proteins as described comprise a SIRPα extracellular component and hydrophobic and intracellular components comprising transmembrane and/or signaling domains of a CD28, respectively. Such fusion proteins are capable of delivering a positive or costimulatory signal in response to a binding event that in a natural setting would result in an inhibitory signal. Uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease, are also described.
-
96.发明授权公开(公告)号：US11993794B2
公开(公告)日：2024-05-28
申请号：US17203473
申请日：2021-03-16
发明人： Rupesh Amin
IPC分类号： C12N9/52 , C07K14/705 , C07K16/00 , C07K16/44 , C07K16/46 , C12N9/50 , C12N9/64 , C12N9/96 , C12N15/70 , C12N15/81
CPC分类号： C12N9/52 , C07K14/705 , C07K16/005 , C07K16/44 , C07K16/468 , C12N9/50 , C12N9/6472 , C12N9/96 , C07K2317/22 , C07K2317/32 , C07K2317/569 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/61 , C07K2319/70 , C07K2319/71 , C07K2319/715 , C07K2319/80 , C12N15/70 , C12N15/81
摘要： Methods to create chemically-induced dimerizing (CID) protein systems and uses thereof are described. The methods utilize antibody binding domain dimerizing proteins. The created systems can be used to regulate cellular events such as gene expression, receptor signaling and cell death to effectuate a variety of clinically relevant treatment outcomes.
-
公开(公告)号：US20240165255A1
公开(公告)日：2024-05-23
申请号：US18491703
申请日：2023-10-20
发明人： Soheil Meshinchi , Quy Le
CPC分类号： A61K47/6849 , A61K47/6817 , A61K47/6889 , A61P35/02
摘要： Methods and compositions for providing a cytotoxic effect against FOLR-1 expressing cancers using antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs are provided. Examples of FOLR-1 expressing cancers include leukemias, ovarian cancer, breast cancer, bladder cancer, and lung cancer, among other cancers described herein.
-
98.发明公开公开(公告)号：US20240122984A1
公开(公告)日：2024-04-18
申请号：US18403553
申请日：2024-01-03
发明人： Matthias Stephan
IPC分类号： A61K35/17 , A01K67/0271 , A61K9/00 , A61K9/14 , A61K39/44 , A61K45/06 , C07K16/28 , C12N5/09
CPC分类号： A61K35/17 , A01K67/0271 , A61K9/0024 , A61K9/146 , A61K39/44 , A61K45/06 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C12N5/0694 , A01K2207/12 , A01K2227/105 , A01K2267/0331 , C12N2510/00 , C12N2533/54 , C12N2533/74
摘要： The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.
-
公开(公告)号：US20240092941A1
公开(公告)日：2024-03-21
申请号：US18350617
申请日：2023-07-11
发明人： Jason Price , Colin E. Correnti , James M. Olson
IPC分类号： C07K16/46
CPC分类号： C07K16/468 , C07K2317/31 , C07K2317/52 , C07K2317/565 , C07K2317/569
摘要： Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging/diagnostic agents.
-
公开(公告)号：US11905511B2
公开(公告)日：2024-02-20
申请号：US16023010
申请日：2018-06-29
IPC分类号： C12N15/10 , G16B40/00 , C12Q1/6883 , C12Q1/6874 , C12Q1/6869 , C12Q1/6881
CPC分类号： C12N15/1065 , C12Q1/6869 , C12Q1/6874 , C12Q1/6881 , C12Q1/6883 , G16B40/00 , C12Q2600/16
摘要： A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it. This method is based on quantifying T-cell diversity by calculating the number of diverse T-cell receptor (TCR) beta chain variable regions from blood cells.
-
-
-
-
-
-
-
-
-
搜索结果
112 条记录 (耗时 0.033 秒)
